Javascript must be enabled to continue!
1752-P: GDF11 Involved in Expressed MicroRNAs during GLP-1RA Inhibited Adipogenesis
View through CrossRef
Differentiation of bone marrow mesenchymal stem cells (BMSCs)is controlled by a vast array of mechanisms, with miRNAs-mRNAs regulation network identified widely recently. In this study, we aimed to specify the differentially expressed (DE) miRNAs after glucagon-like peptide-1 receptor agonist (GLP-1RA) administration during adipogenesis in BMSCs. MiRNAs extracted from three different groups, [the control group (C), the adipogenesis group (A), and the GLP-1RA administration group (GA)], were sent for high-throughput sequencing. We identified 5 DE miRNAs (miRNA-150-5p, miRNA-129-5p, miRNA-201-3p, miRNA-201-5p, and miRNA-214-5p) among groups. The expression of the 5 DE miRNAs were verified by the real-time RT-PCR analysis and consistent with the small-RNA sequencing data. Target genes were then predicted, and highly enriched GOs and KEGG pathway analyses indicated that they were involved in multiple biological processes concerning adipogenesis. Two of the target genes, growth differentiation factor 11 (GDF11) and cholecystokinin B receptor (CCKBR), were verified for functional study. Actually, the mRNA levels of GDF11, rather than CCKBR, was down-regulated by miRNA-150-5pand involved in GLP-1RA administration. Taken together, these results suggested for the first time that GDF11 was involved in differentially expressed microRNAs during GLP-1RA inhibited adipogenesis in primary BMSCs.
Disclosure
P. Xue: None. N. Wang: None. Z. Li: None. S. Li: None. L. Yukun: None.
Funding
Natural Science Foundation of Hebei Province (H2016206243); Department of Health of Hebei Province (361005)
Title: 1752-P: GDF11 Involved in Expressed MicroRNAs during GLP-1RA Inhibited Adipogenesis
Description:
Differentiation of bone marrow mesenchymal stem cells (BMSCs)is controlled by a vast array of mechanisms, with miRNAs-mRNAs regulation network identified widely recently.
In this study, we aimed to specify the differentially expressed (DE) miRNAs after glucagon-like peptide-1 receptor agonist (GLP-1RA) administration during adipogenesis in BMSCs.
MiRNAs extracted from three different groups, [the control group (C), the adipogenesis group (A), and the GLP-1RA administration group (GA)], were sent for high-throughput sequencing.
We identified 5 DE miRNAs (miRNA-150-5p, miRNA-129-5p, miRNA-201-3p, miRNA-201-5p, and miRNA-214-5p) among groups.
The expression of the 5 DE miRNAs were verified by the real-time RT-PCR analysis and consistent with the small-RNA sequencing data.
Target genes were then predicted, and highly enriched GOs and KEGG pathway analyses indicated that they were involved in multiple biological processes concerning adipogenesis.
Two of the target genes, growth differentiation factor 11 (GDF11) and cholecystokinin B receptor (CCKBR), were verified for functional study.
Actually, the mRNA levels of GDF11, rather than CCKBR, was down-regulated by miRNA-150-5pand involved in GLP-1RA administration.
Taken together, these results suggested for the first time that GDF11 was involved in differentially expressed microRNAs during GLP-1RA inhibited adipogenesis in primary BMSCs.
Disclosure
P.
Xue: None.
N.
Wang: None.
Z.
Li: None.
S.
Li: None.
L.
Yukun: None.
Funding
Natural Science Foundation of Hebei Province (H2016206243); Department of Health of Hebei Province (361005).
Related Results
Renal vasodilation induced by Glucagon‐like peptide‐1 is mediated only by the known receptor
Renal vasodilation induced by Glucagon‐like peptide‐1 is mediated only by the known receptor
Glucagon‐like peptide‐1 (GLP‐1) stimulates insulin release after a meal. The GLP‐1 receptor is found in many tissues including the renal vasculature. GLP‐1 increases renal blood fl...
GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation
GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation
AbstractOsteoporosis is an age-related disease that affects millions of people. Growth differentiation factor 11 (GDF11) is a secreted member of the transforming growth factor beta...
GDF11 Attenuates Development of Type 2 Diabetes via Improvement of Islet β-Cell Function and Survival
GDF11 Attenuates Development of Type 2 Diabetes via Improvement of Islet β-Cell Function and Survival
Growth differentiation factor 11 (GDF11) has been implicated in the regulation of islet development and a variety of aging conditions, but little is known about the physiological f...
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease
Background:
Clinical trials examining the therapeutic benefits of glucagon-like peptide-1 receptor agonists (GLP-1RA) on patients with metabolic associated fatty liver ...
Fluctuation trend of inflammatory indexes related to gestational diabetes mellitus from second trimester to third trimester of pregnancy
Fluctuation trend of inflammatory indexes related to gestational diabetes mellitus from second trimester to third trimester of pregnancy
Abstract
Objective: to explore the changes of serum inflammatory bodies (NLRP3), interleukin-1 receptor antagonist (IL-1Ra) and thioredoxin binding protein-2 (TBP-2) in pre...
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes
<p dir="ltr">Metabolic effects of glucagon-like peptide-1 (GLP-1) receptor agonists are confounded by weight loss and not fully recapitulated by increasing endogenous GLP-1. ...
Abstract 95: Glucagon Like Peptide-1 (GLP-1) Does Not Cause Vasodilation Even When Dipeptidyl Peptidase 4 (DPP4) is Inhibited
Abstract 95: Glucagon Like Peptide-1 (GLP-1) Does Not Cause Vasodilation Even When Dipeptidyl Peptidase 4 (DPP4) is Inhibited
Glucagon-like peptide 1 (GLP-1) causes direct vasodilation in animal models. Dipeptidyl peptidase 4 (DPP4) inhibitors improve glycemic control in diabetic patients by preventing th...
Abstract WP109: Glucagon-Like Peptide-1 Has Anti-Inflammatory Effects Through Increasing IB1, A Scaffold Regulator Of JNK, In Cerebral Ischemia
Abstract WP109: Glucagon-Like Peptide-1 Has Anti-Inflammatory Effects Through Increasing IB1, A Scaffold Regulator Of JNK, In Cerebral Ischemia
Background and Purpose:
Hyperglycemia is frequently observed in patients with acute ischemic stroke, and conversely, diabetic patients showed a high frequency of stroke...

